Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Aim and scope
3. Overview of presentation
4. Background and context
5. Osteoarthritis (OA) (1)
6. Osteoarthritis (OA) (2)
7. Osteoarthritis (OA) (3)
8. Risk factors for OA
9. Obesity and OA
10. General features of OA
11. Loss of homeostasis leads to OA
12. The cytokine balance is perturbed in OA
13. Repetitive excess mechanical loading
14. Synovial, chondral and subchondral changes
15. Biomarker: definition
16. Rationale for development of OA biomarkers
17. The gold standard (radiography) is inadequate
18. A better "gold standard"
19. Limitations of radiography
20. Rationale for identifying early OA biomarkers
21. Classification of OA biomarkers: BIPEDs
22. Osteoarthritis biomarkers network classification
23. OA biomarkers working group
24. Classification of OA biomarkers
25. Relevance of biomarkers for clinicians & patients
26. Relevance to pharmaceutical product pipeline
27. The drug pipeline
28. Challenges facing the drug pipeline
29. The OA drug pipeline
30. Surrogate OA biomarkers
31. Biochemical marker toolbox in drug discovery
32. The biomarker pipeline
33. Major classes of OA biomarkers
34. Soluble OA biomarkers
35. BIPED biomarkers classification
36. Classifying biomarkers according to tissue of origin
37. Not all biomarkers indicate cartilage catabolism
38. The matrisome
39. Biomarkers origin: synovial tissues and cells
40. Proteomic strategies to identify OA biomarkers
41. Differences between OA and RA
42. Identification of novel serum OA biomarkers
43. Complement proteins as OA biomarkers
44. Complement components expression in OA
45. Barriers to biomarkers achieving their full potential
46. Challenges to OA biomarker discovery
47. Performance and measurement of markers
48. Summary
49. Conclusions (1)
50. Conclusions (2)
51. Current progress and existing bottlenecks
52. Future priorities
53. Biomarker combinations
54. Biomarkers of joint overuse and injury
55. Take home message
56. Acknowledgements

Topics Covered

• Diagnosis of osteoarthritis
• Issues with radiographic diagnosis
• Lack of analytical tools and reagents for diagnosis
• Limitations of current biomarkers
• Future opportunities for the pharmaceutical industry

Links

Series:

• Biomarkers

Categories:

• Clinical Practice

Talk Citation

Publication History

• Published on January 24, 2013

Financial Disclosures

• Dr. Ali Mobasheri has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.